Literature DB >> 22157854

Neurotherapeutics.

Gwenn S Smith, Xiaohua Li, P Jeffrey Conn.   

Abstract

Mesh：

Year:  2012        PMID： 22157854      PMCID： PMC3238089          DOI： 10.1038/npp.2011.233

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN： 0893-133X            Impact factor:   7.853


× No keyword cloud information.
  10 in total

Review 1.  Networking in autism: leveraging genetic, biomarker and model system findings in the search for new treatments.

Authors:  Jeremy Veenstra-VanderWeele; Randy D Blakely
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

Review 2.  Alzheimer's therapeutics: translation of preclinical science to clinical drug development.

Authors:  Alena V Savonenko; Tatiana Melnikova; Andrew Hiatt; Tong Li; Paul F Worley; Juan C Troncoso; Phil C Wong; Don L Price
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

Review 3.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 4.  From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment.

Authors:  Bita Moghaddam; Daniel Javitt
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 5.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 6.  Review of pharmacological treatment in mood disorders and future directions for drug development.

Authors:  Xiaohua Li; Mark A Frye; Richard C Shelton
Journal:  Neuropsychopharmacology       Date:  2011-09-07       Impact factor: 7.853

Review 7.  Novel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulation.

Authors:  Giovanni Addolorato; Lorenzo Leggio; F Woodward Hopf; Marco Diana; Antonello Bonci
Journal:  Neuropsychopharmacology       Date:  2011-10-26       Impact factor: 7.853

Review 8.  Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior.

Authors:  Ebrahim Haroon; Charles L Raison; Andrew H Miller
Journal:  Neuropsychopharmacology       Date:  2011-09-14       Impact factor: 7.853

Review 9.  Cognitive training for impaired neural systems in neuropsychiatric illness.

Authors:  Sophia Vinogradov; Melissa Fisher; Etienne de Villers-Sidani
Journal:  Neuropsychopharmacology       Date:  2011-11-02       Impact factor: 7.853

Review 10.  Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond.

Authors:  Christina Gross; Elizabeth M Berry-Kravis; Gary J Bassell
Journal:  Neuropsychopharmacology       Date:  2011-07-27       Impact factor: 7.853
  10 in total
  1 in total

Review 1.  Cholinergic interneurons in the dorsal and ventral striatum: anatomical and functional considerations in normal and diseased conditions.

Authors:  Kalynda K Gonzales; Yoland Smith
Journal:  Ann N Y Acad Sci       Date:  2015-04-15       Impact factor: 5.691
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.